A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer

British Journal of Cancer

Volumn 73, Issue 2, 1996, Pages 210-216

  Adachi, I ^a,f   Watanabe, T ^a,f   Takashima, S ^b,f   Narabayashi, M ^a,f   Horikoshi, N ^c,f   Aoyama, H ^d,f   Taguchi, T ^e,g  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^c CANCER INSTITUTE HOSPITAL   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^e Japan Soc for Cancer Chemotherapy   (Japan)

^f RP56976 Clin Stud Grp B Breast C   (Japan)

^g Japan Clin Study Group for RP56976   (Japan)

Author keywords

Chemotherapy; Docetaxel; Metastatic breast cancer; Phase II study

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; DOCETAXEL;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CLINICAL TRIAL; DRUG EFFICACY; EDEMA; FATIGUE; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; VOMITING;

EID: 0030040267     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.37     Document Type: Article

References (24)

1. BISSERY M-C, GUENARD D, GUERITTE-VOEGELEIN F AND LAVELLE F. (1991). Experimental antitumour activity of taxotere(RP56976, NSC628503), a taxol analogue. Cancer Res., 51, 4845-4852.
2. BURRIS H, IRVIN R, KUHN J, KALTER S, SMITH L, SHAFFER D, FIELDS S, WEISS G, ECKARDT J, RODRIGUEZ G, RINALDI D, WALL J, COOK G, SMITH S, VREELAND F, BAYSSAS M, LEBAIL N AND VON HOFF D. (1993). Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J. Clin. Oncol., 11, 950-958.
3. DIERAS V, FUMOLEAU P, CHEVALLIER B, KERBRAT P, KRAKOWSKY Y, ROCHE H, MISSET JL, LENTZ MA, AZLI N AND POUILLART P. (1994). Second EORTC-clinical screening group(CSG) phase II trial of Taxotere (docetaxel) as first line chemotherapy in advanced breast cancer (ABC). Proc. Am. Soc. Clin. Oncol., 13, 78(115).
4. FUMOLEAU P, CHEVALLIER B, KERBRAT P, DIERAS V, LE BAIL N, BAYSSAS M AND VAN GLABBEKE M. (1993). First line chemotherapy with taxotere(T) in advanced breast cancer(ABC): a phase II study of the EORTC clinical screening group(CSG). Proc. Am. Soc. Clin. Oncol., 12, 56(27).
5. FURUE H, HARA Y, IMAI Y, KIMURA T, KOYAMA Y, KURIHARA M, MAJIMA H, NAKAO I, NIITANI H, OGAWA M, ONOSHI T, SAITO T, SAKAI Y, SAKANO T, SAKUMA A, TAKAYA O, TOMINAGA S AND YOKOYAMA M., eds. (1986a). Criteria for the evaluation of direct effects of solid cancer chemotherapy (in Japanese) J. Jpn. Soc. Cancer Ther., 21, 931-942. (English translated version: J. Jpn. Soc. Cancer Ther., 28, 105-118, 1993).
6. FURUE H, HARA Y, IMAI Y, KIMURA T, KOYAMA Y, KURIHARA M, MAJIMA H, NAKAO I, NIITANI H, OGAWA M, ONOSHI T, SAITO T, SAKAI Y, SAKANO T, SAKUMA A, TAKAYA O, TOMINAGA S AND YOKOYAMA M., eds. (1986a). Criteria for the evaluation of direct effects of solid cancer chemotherapy (in Japanese) J. Jpn. Soc. Cancer Ther., 21, 931-942. (English translated version: J. Jpn. Soc. Cancer Ther., 28, 105-118, 1993).
7. FURUE H, HARA Y, IMAI Y, KIMURA T, KOYAMA Y, KURIHARA M, MAJIMA H, NAKAO I, NIITANI H, OGAWA M, ONOSHI T, SAITO T, SAKAI Y, SAKANO T, SAKUMA A, TAKAYA O, TOMINAGA S AND YOKOYAMA M., eds. (1986b). Criteria for the evaluation of effect reinforcement of solid cancer chemotherapy (in Japanese) J. Jpn. Soc. Cancer Ther., 21, 943-953. (English translated version: J. Jpn. Soc. Cancer Ther., 28, 119-130, 1993).
8. FURUE H, HARA Y, IMAI Y, KIMURA T, KOYAMA Y, KURIHARA M, MAJIMA H, NAKAO I, NIITANI H, OGAWA M, ONOSHI T, SAITO T, SAKAI Y, SAKANO T, SAKUMA A, TAKAYA O, TOMINAGA S AND YOKOYAMA M., eds. (1986b). Criteria for the evaluation of effect reinforcement of solid cancer chemotherapy (in Japanese) J. Jpn. Soc. Cancer Ther., 21, 943-953. (English translated version: J. Jpn. Soc. Cancer Ther., 28, 119-130, 1993).
9. GREGORY WM, SMITH P, RICHARDS MA, TWELVES CJ, KNIGHT RK AND RUBENS RD. (1993). Chemotherapy of advanced breast cancer: outcome and prognostic factors. Br. J. Cancer, 68, 988-995.
10. GUENARD D, GUERITTE-VOEGELEIN F, AND POTIER P. (1993). Taxol and taxotere: discovery, chemistry, and structure-activity relationships. Acc. Chem. Res., 26, 160-167.
11. HOLMES FA, WALTERS RS, THERIAULT RL, FORMAN AD, NEWTON LK, RABER MN, BUZDAR AU, FRYE DK AND HORTOBAGYI GN. (1991). Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J. Natl Cancer Inst., 83, 1797-1805.
12. KANDA K, YAMAGATA J, TAKENAKA K, TASHIRO H AND NOMURA Y. (1981). Combination chemotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide (FAC). Jpn. J. Cancer Chemother., 8, 749-756.
13. KELLAND LR AND ABEL G. (1992). Comparative in vitro cytotoxicity of taxol and taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother. Pharmacol., 30, 444-450.
14. KUBO K, ABE O, IZUO M, ENOMOTO K, KOYAMA H, SAKAI K, TERASAWA T, TOMINAGA T AND NOMURA Y. (1983). Clinical evaluation of adriamycin for advanced breast cancer. III. A joint study by 26 institutes on the 'CAF' and 'CMcF' regimens. Jpn. J. Cancer Chemother., 10, 2523-2531.
15. PAZDUR R, KUDELKA AP, KAVANAGH JJ, COHEN PR AND RABER MN. (1993). The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat. Rev., 19, 351-386.
16. PICCART MJ. (1993). Taxotere: a second generation taxoid compound. In ASCO Educational Book, Dalton, WS et al. eds, pp. 25-32. American Society of Clinical Oncology.
17. RINGEL I AND HORWITZ SB. (1991). Studies with RP56976 (taxotere): a semisynthetic analogue of taxol. J. Natl Cancer Inst., 83, 288-291.
18. SKIDMAN AD, HUDIS C, CROWN JPA, BALMACEDA C, LEBWOHL D, CURRIE V, GILEWSKI T, HAKES T, RUBLES M, KLEM K, LEPORE J AND NORTON L. (1993). Phase II evaluation of taxotere (RP56976, NSC628503) as initial chemotherapy for metastatic breast cancer. Proc. Am. Soc. Clin. Oncol., 12, 63(52).
19. TAGUCHI T, FURUE H, NIITANI H, ISHITANI K, KANAMARU R, HASEGAWA K, ARIYOSHI H, NODA K, FURUSE K, FUKUOKA M, YAKUSHIJI MANDKASHIMURA M. (1994a). Phase I clinical trial of RP56976 (docetaxel), a new anticancer drug (in Japanese, abstract in English). Jpn. J. Cancer Chemother., 21, 1997-2005.
20. TAGUCHI T, HIRATA K, KUNII Y, TABEI T, SUWA T, KITAJIMA M, ADACHI I, TOMINAGA T, SHIMADA H, SANO M, MIURA S, TAKAI S, KINOSHITA H, MATSUNAGA S, KONISHI Y, SONOO H, HIRAKI T, TOGE T, TAKASHIMA S, TANAKA M, OGAWA M AND OTA J. (1994b). An early phase II clinical study of RP56976 (docetaxel) in patients with breast cancer (in Japanese, abstract in English). Jpn. J. Cancer Chemother., 21, 2453-2460.
21. TAGUCHI T, MORI S, ABE R, HASEGAWA K, MORISHITA Y, TABEI T, SASAKI Y, FUJITA M, ENOMOTO K, HAMANO K, TOMINAGA T, SASAKI T, YAMAGUCHI S, NISHIYAMA K, UDA F, KANDA K, TAKAGI H, MASAOKA A, TAKAHASHIT, OKAT, TAKAI S, OTA J, WADA T, YAYOI K, NAITO Y, KONISHI Y, SONOO H, HIRAKI S, YAMAMOTO Y, NAKASE A, DOHI K, MONDEN Y AND OGAWA M. (1994c). Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer (in Japanese, abstract in English). Jpn. J. Cancer Chemother., 21, 2625-2632.
22. TRUDEAU ME, EISENHAUER E, LOFTERS W, NORRIS B, MULDAL A, LETENDRE F, VANDENBURG T AND VREMA S. (1993). Phase II study of taxotere as first line chemotherapy for metastatic breast cancer (MBC). A national cancer institute of Canada clinical trials group (NCIC CTG) study. Proc. Am. Soc. Clin. Oncol., 12, 64 (59).
23. WANDERS J, SCHRIJVERS D. BRUNTSCH U, GORE M, VERWEIJ J, HANAUSKE AR, FRANKLIN H, ROELVINK M, BAYSSAS M AND KAYE SB. (1993). The EORTC ECTG experience with acute hypersensitivity reactions (HSR) in taxotere studies. Proc. Am. Soc. Clin. Oncol., 12, 73 (94).
24. WEISS RB, DONEHOWER RC, WIERNIK PH, OHNUMA T, GRELLA RJ, TRUMP DL, BAKER JR Jr, VANECHO DA, VONHOEF DD AND LEYLAND-JONES B. (1990). Hypersensitivity reactions from taxol. J. Clin. Oncol., 8, 1263-1268.